Fact CheckerSign in

NCT05463757Recruiting

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

Registration of Oral Hedgehog Inhibitors Vismodegib and Sonidegib in the Treatment of Advanced and Multiple Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study.

Source: ClinicalTrials.gov · Last updated 4 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients. In the Netherlands, targeted therapy with vismodegib and sonidegib has been available since 2013 and 2021, respectively. No direct comparative studies have been performed between the two oral hedgehog inhibitors (HHI) vismodegib and sonidegib yet . In addition, data for sonidegib are not yet available. Objective: The aim of this study is 1) to evaluate the effectiveness of oral HHIs in the treatment of laBCC, mBCC and BCNS patients and 2) to compare the oral HHIs vismodegib and sonidegib. Study design: prospective registration study that includes all patients, regardless of age and gender, with histologically proven basal cell carcinoma receiving treatment with either vismodegib or sonidegib in the Netherlands. Patient, tumor and treatment information was gathered from patient records. Main study parameters/endpoints: The primary outcome for measuring efficacy/tumor response was median progression free survival (PFS) where the decrease, stagnation or increase in tumor size is measured by maximum diameter. Secondary outcomes are frequency, severity and reversibility of treatment-emergent adverse events and disease-specific quality of life expressed as mean scores on the EORTC-QLQ-C30 and aBCCdex questionnaires.

Status (registry)
Recruiting
Study type
Observational
Enrollment
80 (estimated)
First submitted
31 May 2022
Start date
1 Nov 2021
Primary completion date
Jun 2026
Lead sponsor
Maastricht University Medical Center
NCT number
NCT05463757

What you commit to

  • Study type: Observational
  • Planned participants: 80
  • From 1 Nov 2021 to the primary completion date, Jun 2026
  • 8 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • None

Who the study is looking for

  • Men and women
  • All ages
  • Diagnosed with locally advanced basal cell carcinoma (laBCC), metastatic basal cell carcinoma (mBCC), multiple basal cell carcinomas or Gorlin syndrome
  • Use of oral hedgehog inhibitor vismodegib or sonidegib

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (8)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Amsterdam UMC
Coordinator of this site? Confirm its status
AmsterdamNetherlandsRecruiting
Netherlands Cancer Institute - AVL
Coordinator of this site? Confirm its status
AmsterdamNetherlandsRecruiting
UMCG
Coordinator of this site? Confirm its status
GroningenNetherlandsNot yet recruiting
LUMC
Coordinator of this site? Confirm its status
LeidenNetherlandsRecruiting
Maastricht University Medical Center
Coordinator of this site? Confirm its status
MaastrichtNetherlandsRecruiting
Radboudumc
Coordinator of this site? Confirm its status
NijmegenNetherlandsRecruiting
Erasmus MC
Coordinator of this site? Confirm its status
RotterdamNetherlandsRecruiting
UMC Utrecht
Coordinator of this site? Confirm its status
UtrechtNetherlandsRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.